Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.70 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | SELP | P16109 | 2/20 | 0.45 |
| ▸ | SELE | P16581 | 2/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5153814 | 0.88 | EPHX2 (0.67) | EPHX2ENPP2KMT2AMGLL | |
| SCHEMBL2744086 | 0.88 | EPHX2 (0.73) | EPHX2ENPP2KMT2AMGLL | |
| SCHEMBL30877549 | 0.87 | EPHX2 (0.72) | EPHX2KMT2AMGLL | |
| SCHEMBL29679600 | 0.86 | EPHX2 (0.60) | EPHX2ENPP2KMT2ANR1H4CASP3 | |
| SCHEMBL1001375 | 0.86 | EPHX2 (0.60) | EPHX2ENPP2KMT2ANR1H4CASP3 | |
| SCHEMBL20788951 | 0.86 | EPHX2 (0.65) | EPHX2ENPP2KMT2AMGLLCASP3 | |
| SCHEMBL28865314 | 0.85 | EPHX2 (0.64) | EPHX2ENPP2KMT2AMGLLCASP3 | |
| SCHEMBL30051640 | 0.85 | EPHX2 (0.64) | EPHX2ENPP2KMT2AMGLLCASP3 | |
| SCHEMBL8366872 | 0.85 | EPHX2 (0.75) | EPHX2KMT2ACASP3 | |
| SCHEMBL30422053 | 0.83 | KMT2A (0.56) | EPHX2ENPP2KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-01 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3052515-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | The Regents of the University of California (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015048819-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048819-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) | 2012-12-06 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-6649613-B1 | Integrin inhibitors | MERCK PATENT GMBH (DE) | 2003-11-18 | — | — | US | disclosed |
| EP-1194401-B1 | DIACYLHYDRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-09-10 | — | — | EP | disclosed |
| EP-1194401-A1 | DIACYLHYDRAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-04-10 | — | — | EP | disclosed |
| US-6326403-B1 | CARDIOVASCULAR DISORDERS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2001-12-04 | — | — | US | disclosed |
| CN-1309633-A | Diacylhydrazine derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2001-08-22 | — | — | CN | disclosed |
| WO-2001005753-A1 | DIACYLHYDRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | EPHX2 2825/4885ENPP2 427/4885KMT2A 3854/4885 |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | MMP3, MMP11, TIMP3 | EPHX2 581/4885ENPP2 84/4885KMT2A 3532/4885 |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | ITGB1, ITGAV, ITGA1 | EPHX2 2825/4885ENPP2 427/4885KMT2A 3854/4885 |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | EPHX2 2825/4885ENPP2 427/4885KMT2A 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.